- Business Wire•2 days ago
BioTime, Inc. , a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that it will release third quarter financial and operating results on Thursday, November 3, 2016, after the close of the U.S.
- Business Wire•6 days agoFirst Patient Cohort Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to Be Presented at ISOPT Clinical Symposium on December 2, 2016
BioTime, Inc. , a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today reported that data from the first patient cohort of the Phase I/IIa clinical trial of OpRegen® in the advanced form of dry age-related macular degeneration will be presented at the International Symposium on Ocular Pharmacology and Therapeutics on Friday, December 2, 2016, in Rome, Italy....
- Business Wire•8 days ago
LifeMap Solutions, the digital health subsidiary of BioTime, Inc. , today announced a partnership with Medidata , the leading provider of cloud-based solutions for clinical research.
BioTime, Inc. (BTX)
NYSE MKT - NYSE MKT Real Time Price. Currency in USD
|Bid||3.54 x 100|
|Ask||3.57 x 100|
|Day's Range||3.52 - 3.56|
|52wk Range||2.02 - 4.51|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-15.09|
|Avg Vol (3m)||286,595|
|Dividend & Yield||N/A (N/A)|